Manny Simons, Akouos CEO (Webb Chappell/Harvard Business School)
October 18, 2022 07:33 AM EDTUpdated 10:05 AM
Deals
Cell/Gene Tx

Up­dat­ed: Not known for gene ther­a­py plays, Eli Lil­ly ac­quires hear­ing loss start­up Ak­ou­os for $487M plus CVR

Max Gelman

Senior Editor

Eli Lil­ly is jump­ing in­to gene ther­a­pies for the ear.

The Big Phar­ma an­nounced ear­ly Tues­day that it will ac­quire Boston biotech Ak­ou­os for a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times